Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation

References

• De Brabander M, Geuens G, Nuydens R, et al. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci 1981;78:5608–5612
   PubMed Web of Science ®Google Scholar
• Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123–6131
   PubMed Web of Science ®Google Scholar
• Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147
   PubMed Web of Science ®Google Scholar
• Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746–1752
   PubMed Web of Science ®Google Scholar
• Ooya T, Lee J, Park K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003;93:121–127
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590–1598
   PubMed Web of Science ®Google Scholar
• Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437–438
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Rajkumar SV, eds. The high cost of cancer drugs and what we can do about it. Mayo Clinic Proceedings. Amsterdam: Elsevier; 2012
   Google Scholar
• Werner ME, Cummings ND, Sethi M, et al. Preclinical evaluation of genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013;86:463–468
   PubMed Web of Science ®Google Scholar
• Wan Y, Zheng Y, Song X, et al. Anti-tumor activity of biodegradable polymer-paclitaxel conjugate micelles on lewis lung cancer mice models. J Biomater Sci Polym Ed 2011;22:1131–1146
   PubMed Web of Science ®Google Scholar
• Alani AW, Bae Y, Rao DA, Kwon GS. Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. Biomaterials 2010;31:1765–1772
   PubMed Web of Science ®Google Scholar
• Yan F, Li L, Deng Z, et al. Paclitaxel-liposome loaded microbubbles for ultrasound-triggered drug delivery in vitro and in vivo. J Acoust Soc Am 2012;131:3366
   Google Scholar
• Latimer P, Menchaca M, Snyder RM, et al. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med 2009;234:1244–1252
   PubMed Web of Science ®Google Scholar
• Sheihet L, Garbuzenko OB, Bushman J, et al. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. Eur J Pharm Sci 2012;45:320–329
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Rel 2009;133:11–17
   PubMed Web of Science ®Google Scholar
• Erez R, Segal E, Miller K, et al. Enhanced cytotoxicity of a polymer–drug conjugate with triple payload of paclitaxel. Bioorg Med Chem 2009;17:4327–4335
   PubMed Web of Science ®Google Scholar
• Teow HM, Zhou Z, Najlah M, et al. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 2013;441:701–711
   PubMed Web of Science ®Google Scholar
• Lim J, Lo S-T, Hill S, et al. Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. Mol Pharm 2012;9:404–412
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147–156
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Therap 2008;30:1426–1447
   PubMed Web of Science ®Google Scholar
• Bilancia D, Rosati G, Dinota A, et al. Lapatinib in breast cancer. Ann Oncol 2007;18:26–30
   Web of Science ®Google Scholar
• Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012;2012:915375
   PubMedGoogle Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544–5552
   PubMed Web of Science ®Google Scholar
• Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905–7914
   PubMed Web of Science ®Google Scholar
• Collins DM, Crown J, O’Donovan N, et al. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Investig New Drugs 2010;28:433–444
   PubMed Web of Science ®Google Scholar
• Perry J, Ghazaly E, Kitromilidou C, et al. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Therap 2010;9:3322–3329
   PubMed Web of Science ®Google Scholar
• Vergara D, Bellomo C, Zhang X, et al. Lapatinib/paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomed Nanotechnol Biol Med 2012;8:891–899
   PubMed Web of Science ®Google Scholar
• Li F, Danquah M, Singh S, et al. Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res 2011;1:420–428
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271–284
   PubMed Web of Science ®Google Scholar
• Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev 1995;16:295–309
   Web of Science ®Google Scholar
• Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 1996;21:107–116
   Web of Science ®Google Scholar
• Alakhova DY, Rapoport NY, Batrakova EV, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release 2010;142:89–100
   PubMed Web of Science ®Google Scholar
• Basu Ray G, Chakraborty I, Moulik SP. Pyrene absorption can be a convenient method for probing critical micellar concentration (cmc) and indexing micellar polarity. J Colloid Interface Sci 2006;294:248–254
   PubMed Web of Science ®Google Scholar
• Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 1996;132:195–206
   Web of Science ®Google Scholar
• Atkinson AC, Donev AN, Tobias RD. Optimum experimental designs, with SAS. Oxford: University Press Oxford; 2007
   Google Scholar
• Mitchell TJ. An algorithm for the construction of “D-optimal” experimental designs. Technometrics 1974;16:203–210
   Web of Science ®Google Scholar
• Wei Z, Hao J, Yuan S, et al. Paclitaxel-loaded pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int J Pharm 2009;376:176–185
   PubMed Web of Science ®Google Scholar
• Chen L, Sha X, Jiang X, et al. Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomed 2013;8:73–84
   PubMed Web of Science ®Google Scholar
• D’Souza SS, DeLuca PP. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharma Res 2006;23:460–474
   Google Scholar
• Liu Y, Sun J, Cao W, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharma 2011;421:160–169
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82:189–212
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Y, Hou S, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008;69:445–453
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Y, Wu W, et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm 2008;350:320–329
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu L, Han L, et al. Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 2007;337:63–73
   PubMed Web of Science ®Google Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136:21–29
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116:275–284
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Garnett MC, et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999;57:171–185
   PubMed Web of Science ®Google Scholar
• Albanese A, Sykes EA, Chan WC. Rough around the edges: the inflammatory response of microglial cells to spiky nanoparticles. ACS Nano 2010;4:2490–2493
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Calleja P, Agüeros M, et al. Stabilized micelles as delivery vehicles for paclitaxel. Int J Pharm 2012;436:258–264
   PubMed Web of Science ®Google Scholar
• Zhang L, Fan C, Guo Z, et al. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. Eur J Med Chem 2013;69:833–841
   PubMed Web of Science ®Google Scholar
• Sartorius CA, Groshong SD, Miller LA, et al. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994;54:3868–3877
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58
   PubMed Web of Science ®Google Scholar
• Zhang W, Shi Y, Chen Y, et al. Multifunctional pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011;32:2894–2906
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310–1316
   PubMed Web of Science ®Google Scholar